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Background
Within the last recent years biopharmaceutical sales have
reached 30% of all new pharmaceutical sales in the
United States expecting an increase from 30 billion USD
(2003) to almost 60 billion USD until 2010 [1]. One
major industry of the fast growing biopharmaceutical
market is the manufacture of recombinant proteins for
therapeutic and diagnostic use. Hence, the rising demand
for new biopharmaceuticals requires increased produc-
tion capacities as well as new production processes that
exhibit increased space-time yields and shortened devel-
opment times which also implies the use of suitable
expression systems.
In the 1970s, when recombinant DNA technology found
its way into molecular biology laboratories, the bacterial
cell was prevalently presented as a universal host for het-
erologous protein expression. However, due to their ina-
bility to adequately process complex proteins and due to
their insufficient protein secretion capabilities prokaryotic
expression systems nowadays are mainly used for the pro-
duction of rather uncomplex proteins and peptides. In
order to produce complex human recombinant proteins a
reinforced development of eukaryotic expression systems
has proceeded in the last decades, which was mainly
based on yeast cells and mammalian cells. As a result,
mammalian cell-based biopharmaceuticals account for
almost 60% of today's biopharmaceutical market.
But, what do we really know about the production capac-
ity of a particular host cell related to cell mass and cell vol-
ume? What can we learn in order to ease the choice of a
suitable expression system for a particular protein? How
can we use this knowledge to optimize the product yield
related to process time and space?
We have evaluated different expression systems which
have been technologically used for recombinant protein
production: an inducible prokaryotic expression system
(Escherichia coli) for intracellular human superoxide dis-
mutase [2], an E. coli secretion system for antibody Fab
fragments [3], a constitutive eukaryotic secretion system
(Pichia pastoris) for human trypsinogen and antibody Fab
fragments [4,5] as well as an intracellular P. pastoris system
[6], and a constitutive eukaryotic expression system
(CHO) for an EPO/Fc fusion protein and human mono-
clonal antibodies [7]. We developed production scenarios
for each expression system and compared specific growth
and productivity as well as product secretion rates to
determine the full potential in a bioprocess.
Results
Based on own experience in our labs, as well as on litera-
ture data, we have developed three main scenarios for pro-
tein production, based on E. coli, P. pastoris and CHO cells
as alternative host systems. Maximum and average values
for specific growth rates, specific product formation
(secretion) rates, and space time yields (volumetric pro-
ductivities) are summarized in table 1.
Relating these data to total protein synthesis rates enables
the estimation of the upper limits of production capaci-
ties, while the volumetric productivities inform about the
economic efficiencies of the different scenarios.
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Conclusion
Up to now it was not usual practice to compare mamma-
lian cell culture processes on a common basis with micro-
bial processes. The presented data provide a clear basis to
judge both the economic capabilities of present processes
and the potential and constraints of the different host sys-
tems, pointing the attention to the most severe bottle-
necks that limit the economic feasibility of the respective
production systems. These data enable us to generalize the
understanding of the biological limitations of protein
synthesis and secretion, thus obviating the major poten-
tials for the optimization of currently available expression
systems.
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Table 1: Comparison of typical max. cell dry masses, achieved product concentrations, specific product formation rates and 
volumetric productivities of the selected model processes.
CHO cells P. pastoris P. pastoris E. coli E. coli
Destination of product secreted secreted cytoplasm secreted cytoplasm
[g·L-1] 0.5 – 5 80 – 150 80 – 150 20 35
Typical spec. growth rate [h-1] 0.02 0.02 0.02 0.1 0.1
Typical specific product formation rate [mg·g-1·h-1] 1.5 – 4.5 0.05 – 0.5 4 0.25 – 2.5 20
Product concentration (per culture volume) [g·L-1] 0.1 – 0.5 0.25 – 2.5 20 0.2 – 2 7
Volumetric productivity [mg·L-1·h-1] 1 – 2 (- 25 for perfusion) 1 – 6 (- 25 for continuous 
processes)
160 4 – 40 200Page 2 of 2
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